Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kabi Introduces Idacio Into Crowded German Adalimumab Market

Executive Summary

Fresenius Kabi is entering a German adalimumab market in which Amgen, Mylan and Sandoz are already competing against AbbVie’s Humira reference brand. In this environment, Fresenius’ sales expectations are modest.

You may also be interested in...



The EU's Top Valsartan Lesson: Closely Examine Active Substance Manufacturing Processes

EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.

Kabi Commits To Biosimilars Development

Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.

Fresenius Tempers Expectations For Adalimumab Biosimilar

As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel